Efficacy and safety of amrubicin‐based regimen used as first‐line for extensive‐disease small‐cell lung cancer: A meta‐analysis of randomized controlled trials

Efficacy and safety of amrubicin‐based regimen used as first‐line for extensive‐disease... 1INTRODUCTIONLung cancer is the leading cause of cancer‐related death worldwide, and approximately 12–15% of patients with lung cancer were classified as having small‐cell lung cancer (SCLC). Extensive‐disease (ED)‐SCLC accounts for 60–70% of all SCLC cases, and is characterized by rapid progression. The standard therapy for ED‐SCLC is systemic chemotherapy alone, which could improve the symptom in 60–90% of cases, but most of patients die of the disease within 2 years after diagnosis. Combination therapy, including etoposide in combination with cisplatin or carboplatin, has showed benefic effects in ED‐SCLC. Previous study reported that these regimens resulted in an objective tumor response rate of 73%, and median overall survival (OS) of 10 months. Despite many regimens of targeted therapies and newer chemotherapeutic agents have been developed in the past two decades, the survival outcome for ED‐SCLC patients has not been significantly improved.Amrubicin is a synthetic anthracycline that has demonstrated greater antitumor activity than doxorubicin in several human tumor xenografts implanted in nude mice. Moreover, it almost has no heart damage at cumulative doses, and has no chronic cardiotoxic effects in rabbits and dogs that are found in doxorubicin. A phase 2 study of amrubicin as first‐line therapy showed that amrubicin was http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Asia-Pacific Journal of Clinical Oncology Wiley

Efficacy and safety of amrubicin‐based regimen used as first‐line for extensive‐disease small‐cell lung cancer: A meta‐analysis of randomized controlled trials

Loading next page...
1
 
/lp/wiley/efficacy-and-safety-of-amrubicin-based-regimen-used-as-first-line-for-jpEqfo07Pn
Publisher
Wiley
Copyright
Copyright © 2018 John Wiley & Sons Australia, Ltd
ISSN
1743-7555
eISSN
1743-7563
D.O.I.
10.1111/ajco.12778
Publisher site
See Article on Publisher Site

Abstract

1INTRODUCTIONLung cancer is the leading cause of cancer‐related death worldwide, and approximately 12–15% of patients with lung cancer were classified as having small‐cell lung cancer (SCLC). Extensive‐disease (ED)‐SCLC accounts for 60–70% of all SCLC cases, and is characterized by rapid progression. The standard therapy for ED‐SCLC is systemic chemotherapy alone, which could improve the symptom in 60–90% of cases, but most of patients die of the disease within 2 years after diagnosis. Combination therapy, including etoposide in combination with cisplatin or carboplatin, has showed benefic effects in ED‐SCLC. Previous study reported that these regimens resulted in an objective tumor response rate of 73%, and median overall survival (OS) of 10 months. Despite many regimens of targeted therapies and newer chemotherapeutic agents have been developed in the past two decades, the survival outcome for ED‐SCLC patients has not been significantly improved.Amrubicin is a synthetic anthracycline that has demonstrated greater antitumor activity than doxorubicin in several human tumor xenografts implanted in nude mice. Moreover, it almost has no heart damage at cumulative doses, and has no chronic cardiotoxic effects in rabbits and dogs that are found in doxorubicin. A phase 2 study of amrubicin as first‐line therapy showed that amrubicin was

Journal

Asia-Pacific Journal of Clinical OncologyWiley

Published: Jan 1, 2018

Keywords: ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off